Indivior, a global pharmaceutical manufacturer, has extended its partnership with Siemens to create an automated Active Pharmaceutical Ingredient (API) manufacturing facility at its UK base in Hull. Through this new agreement, Indivior aims to optimize the production of its API Buprenorphine Hydrochloride by implementing three new reactors, filter driers, and a powder transfer system in the 1,731 sq ft facility. This collaboration between the two companies not only focuses on process transformation, but also prioritizes team health and safety.
To achieve this goal, Siemens will introduce its most advanced process control system, SIMATIC PCS neo, which is a web-based platform enabling engineers and operators to work on a secure and user-friendly interface. Additionally, Siemens will preconfigure security measures during the construction phase to safeguard the plant and network while ensuring system integrity. By incorporating the latest technology, the system will also enhance safety controls.
This project in Hull builds on the existing relationship between Indivior and Siemens, which began in 2021 when Siemens was selected by Indivior to enhance automation and process safety at its existing UK manufacturing facility. The successful deployment of Siemens’ SIMATIC PCS 7 process control system at the facility, which currently houses 10 reactors, followed a comprehensive safety study conducted by Indivior.
Alex Caldas, Account Development Manager at Siemens UK and Ireland, affirms the longstanding partnership with Indivior and states, “Crucially, this has meant helping Indivior maintain a safe environment across its facilities, while also enhancing its production to meet ongoing growth ambitions. The SIMATIC PCS 7 and PCS neo technology helps the team make processes even more efficient, safe, and resilient.”
Tom Greatorex, electrical, control, and instrumentation engineer at Indivior, led the project and expressed his satisfaction with Siemens’ process control platforms, PCS7 and PCS neo. He mentions that these platforms enable Indivior to modernize its facilities through digitalization and automation, providing greater insight and control. Greatorex further explains how the creation of the new facility will improve their manufacturing process, reduce bottlenecking, and ensure future-proofed and optimal operations.
Indivior and Siemens are continuing their collaborative efforts to advance pharmaceutical manufacturing through automation, digitalization, and enhanced safety controls. This latest project in Hull highlights the commitment to efficiency, safety, and growth aspirations shared by both companies.
